In his latest article on transkript.de, Dr. Michael H. Thiel takes an exciting look back at the development of German biotechnology – and at the same time offers an optimistic outlook for the coming years.

From the first start-ups in the 1980s to the dynamic start-up scene of the 1990s and today’s global competitiveness, it is clear that German biotechnology has come a long way. Despite challenges such as social skepticism and political hurdles, the industry has established itself as innovative, resilient, and forward-looking.

Particularly encouraging is the fact that biopharmaceuticals now account for over a third of drug sales in Germany – a clear sign of the relevance and success of biotechnological developments.

We would like to thank Dr. Thiel for this insightful contribution and recommend that anyone interested take a look at the full article: To the article on transkript.de

 

The ophthalmology project we are supporting is developing positively. The market entry strategy for Europe is currently being developed.

If you are interested in the project or an investment, please contact us.

Our team is currently supporting an American ophthalmology start-up in its search for capital. The startup is developing a unique system that improves near vision for patients with presbyopia.

If you are interested in investing, we look forward to hearing from you.

Our team member Dr. Michael Thiel is once again a member of the jury for the Munich Business Plan Competition 2022.

Further information on the competition can be found at BayStartUP – Munich Business Plan Competition

SANEMUS supports Medtech Startup, which focuses on innovative biosignal analysis and intelligent medical algorithms in the field of cardiovascular diagnostics, in the search for investors.

If you are interested in the project, we look forward to hearing from you.